June 14, 2015

Friends,

This week’s update on the CLL Society website is my unscripted recording on immunotherapies.

I start by reviewing my take on the good and bad of the well known and novel antibodies directed against our B cells by targeting its surface marker CD20. These include rituximab (Rituxan), ofatumumab (Arzerra), and obinutuzumab (Gazyva).

I also cover other antibodies, new and old, IMIDS (immunomodulatory drugs) such as lenalidomide (Revlimid), vaccines, and more.

Please visit the Treatment section (found under The Basics tab) of the CLL Society website here to access this content.

Please let us know if this helps. I am particularly proud of this recording as it was done live with no notes and therefore I think is more focused, ironically similar to the drugs discussed.

We plan on bringing more of this type of content. Your feedback guides us about what we should add and how we should grow the website.

The artwork in the background is again Will Koffman’s tribute to Durer’s Four Horsemen of the Apocalypse. Will rendered the entire work using only bleach on black cotton.

Thanks

Stay strong.

We are all in the together.

Brian Koffman, MD

Volunteer Medical Director, CLL Society Inc.